Publication for HTN1 and HTN3

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	HTN1	histatin 1	3346			[link]
hsa	HTN3	histatin 3	3347

Pubmed ID	Priority	Text
22605979	0.98	histatin-1, histatin-2, histatin-3 and histatin-5 (this last one is a proteolytic cleavage derivative of histatin-3) accounting for 85-90% of this family.
	0.72	histatin-1 and histatin-3) were also identified as highly important wound closure stimulating factors of human saliva.
24029963	0.97	HTN-1 did not identify any pre-procedure condition capable of predicting RSD success, while in Symplicity HTN-2 the highest SBP values and use of central sympatholytic agents were capable of predicting the procedure success.
	0.76	HTN-1 and Symplicity HTN-2 (HR11) studies, we observed important limitations that need to be considered: a) possible mechanisms responsible for reducing BP at RSD were not investigated in any of the studies; b) there was no control group for Symplicity HTN-1, reducing the relevance of its results; c) at Symplicity HTN-2, due to the complexity of the tested procedure (invasive intervention), the study could not be blind, thus creating a possible evaluation bias; d) in both studies, patients were not properly evaluated for the possibility of secondary AH (it is known that up to 10% of patients with RAH have primary aldosteronism and, in these patients, RAH invasive treatment could be considered; e) only a small number of patients was administering the appropriate clinical therapy for RAH treatment, such as the restriction of salt in diet and use of spironolactone, raising the question whether these patients were really treatment-resistant.
24101882	0.97	HTN-1 and Symplicity HTN-2 trials.
	0.88	HTN-1 and Simplicity HTN-2 trials, RDN was introduced widely in Europe and Australia.
26544073	0.96	histatin 1 and histatin 5 belonging to the same protein family, those proteins present significant differences in post-translational modification and biological activities.
	0.87	histatin 1, a neutral molecule, is a phosphorylated protein with 38 amino acids while histatin 5 is not phosphorylated and has only 24 amino acids.
	0.86	Histatin 1), as well as potent antifungal activities, where histatin 5 is the strongest one following by histatin 3 and 1, respectively.
	0.63	Histatin 1 is generated from HIS 1 gene while histatin 5 is a degradation product from histatin 3 that is generated from the HIS2 gene.
	0.60	histatin 1 with the identified proteins that complex with histatin 5, a total of 14 proteins were common for both.
	0.51	Histatin 5 is described as the major histatin related to the killing of an opportunistic fungus called Candida albicans, while histatin 1 represents the strongest histatin in relation to inhibition of enamel demineralization.
26554798	0.96	HTN-3 trial, a prospective, single-blind, randomized, sham-controlled trial, contradicted those of the Symplicity HTN-1 and HTN-2 trials.
20351356	0.95	histatin 1, histatin 3, and histatin 5) demonstrated more calcium release, but their calcium loss was significantly lower than that observed with the control group (Fig. 3B).
	0.94	histatin 1, histatin 3, and histatin 5 (Fig. 1, lane 4), as well as those of native histatin 1, histatin 3, and histatin 5 present in parotid secretion (Fig. 1, lane 1).
	0.93	histatin 1 and synthetic phosphorylated histatin 3 showed a level of protection significantly higher than that observed for the other groups.
	0.93	histatin 1, histatin 3, and histatin 5 were significant lower than those of the control group (p < 0.05).
	0.87	histatin 1, histatin 3, and histatin 5 in the in vivo AEP is of considerable interest, considering the various biological properties of histatins described so far.
27595156	0.95	HTN-1 and HTN-2 trials reported the blood pressure-lowering effects of RFRD are sustained for at least a 36-month period in relatively small populations with severe treatment resistant hypertension.
	0.52	HTN-3 trial has several advantages over SYMPLICITY HTN-1 and HTN-2, including a larger sample size, inclusion of a control sham procedure, and a single-blinded experimental design.
31049370	0.95	HTN1, HTN3, SMR3A, SMR3B, MUC7).
29125139	0.94	histatin 1, histatin 3 and histatin 5, with 38, 32 and 24 amino-acid residues, respectively.
31754129	0.94	his1 and his2 genes, respectively.
29374335	0.93	HTN-1 and HTN-2 trials that demonstrated a significant decrease in office BP.
	0.88	HTN-1 and Symplicity HTN-2.
	0.72	HTN-1 and Symplicity HTN-2.
	0.58	HTN-1 and HTN-2.
	0.58	HTN-1 and HTN-2.
24474960	0.92	HTN-1 and HTN-2 trials in recent years has provided promising results which demonstrate significant and large decreases in blood pressure in patients with drug-resistant hypertension.
	0.75	HTN-1 and HTN-2 studies demonstrated the good safety profile and efficacy in reducing blood pressure using catheter nerve ablation.
	0.67	HTN-1 and HTN-2 trials have provided strong evidence for renal denervation giving rise to considerable blood pressure reductions in treatment-resistant hypertensives and, due to the high incidence of hypertension worldwide, this carries the promise of further reducing the global burden of hypertension and its attendant complications.
24473528	0.92	HIS1 and HIS2 gene products.
	0.70	histatin 1, 6.0 to 43.0 mug/ml for histatin 3, and 10.0 to 43.0 mug/ml for histatin 5 and concentrations in submandibular and sublingual saliva range from 28.0 to 122.0 mug/ml for histatin 1, 15.0 to 75.0 mug/ml for histatin 3, and 26.0 to 90.0 mug/ml for histatin 5.
25061451	0.91	HTN-1 trial demonstrated the safety and initial efficacy of the procedure in humans and led to the design of the first randomized trial, Symplicity HTN-2.
27165313	0.91	HTN-1 and HTN-2 trials.
25431461	0.89	HTN-1 and HTN-2 provided data for efficacy and safety of RDN, the lack of ABPM in either inclusion criteria or monitoring of BP in response to RDN has been criticised.
	0.58	HTN-1 and HTN-2 studies, the Joint UK Societies produced guidance for the use of RDN in the UK in 2011 which was summarised in an electronically published summary consensus statement.
24683403	0.89	HTN-1 and HTN-2 studies showed that renal denervation (RDN) is feasible as a novel treatment for resistant hypertension.
24244757	0.88	HTN-2 had superior methodology to Symplicity HTN-1, it was limited by a lack of blinding among data analyzers and absence of a sham procedure in the control group.
24974109	0.88	histatin-1, histatin-3, and histatin-5.
19159863	0.87	histatin 1 was highest (median=17.0 mug/ml), followed by histatin 5 (median=6.9 mug/ml) and histatin 3 (median=5.6 mug/ml).
30302103	0.87	HTN-1 and HTN-2 trials did not include only patients with bilateral single arteries.
24369496	0.86	HTN-1 and HTN-2 trials provide much information and are compared in Table 2.
22851728	0.85	HTN-1 and SYMPLICITY HTN-2 studies covered only 6 months.
30664630	0.84	HTN3, and HTN1 with correlating highly active chromatin marks (Fig. 3).
	0.77	HTN3, HTN1) within a single sub-TAD region characterized by abundant active chromatin marks, with inversely orientated CTCF binding sites correlating well with the borders of the sub-TAD regions.
	0.59	HTN3, and HTN1.
28450805	0.80	histatin 1 (HST1), histatin 3 (HST3), and histatin 5 (HST5).
25568521	0.73	HTN-1 and HTN-2 have shown sustained blood pressure reduction at 24 months.
	0.57	HTN-1, Symplicity HTN-2 trial and RSD, activity of the sympathetic nervous system is significantly decreased in both non dipping and reverse dipping patients.
21299198	0.72	histatin 1, and histatin 3.
	0.60	histatin 3 are 79% identical to histatin 1 suggesting that histatin 3 may have similar differential expression, however no peptide of histatin 3 was found in this study to support this possibility.
	0.53	histatin 1, histatin 3, statherin, basic proline rich protein 2, and acidic proline rich protein).
24389229	0.71	HTN-1 and HTN-2) demonstrated 3-month post-RDN improvements in glucose metabolism as well as reduced LV mass and improved diastolic function at 6 months.
20011683	0.70	histatin 3, given the relative stability of the histatin 1 and histatin 5 bands (Fig. 3B).
24570754	0.68	HTN-1 and HTN-2, 209 procedures) included 4 groin pseudoaneurysms (treated with manual compression), 1 renal artery dissection managed with stent implantation without further complications, one urinary tract infection, one postprocedural drop in BP resulting in a reduction in antihypertensive drugs, and one extended hospitalization for assessment of paresthesia.
27583041	0.62	HTN 1 and Symplicity-HTN 2 clinical trials, as well as the Global Symplicity registry, which also demonstrated greater BP reductions in patients with higher baseline BP.
28077386	0.62	HTN-1: BP, 140-159/90-99 or use of 1 or 2 antihypertensive drugs; HTN-2: BP, >=160/100 or use of >=3 drugs).
29662892	0.58	histatin 1 and histatin 5) and with mucins (MUC 5B and MUC 7) were described previously.
31035604	0.58	HTN-1, HTN-2 and HTN-3 trials neither in the SPYRAL HTN-OFF and HTN-ON MED trials.
26824896	0.56	HTN1, HTN3) and numerous peptides translated from these genes.
29651418	0.53	HTN-3 vs -22/-11 mmHg in HTN-1 and -32 +- 23/-12 +- 11 mmHg in HTN-2 at 6 months follow-up).